A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
Open Access
- 23 February 2024
- journal article
- research article
- Published by Springer Nature in npj Precision Oncology
- Vol. 8 (1) , 1-13
Abstract
Brigatinib-based therapy was effective against osimertinib-resistant EGFR C797S mutants and is undergoing clinical studies. However, tumor relapse suggests additional resistance mutations might emerge. Here, we first demonstrated the binding mode of brigatinib to the EGFR-T790M/C797S mutant by crystal structure analysis and predicted brigatinib-resistant mutations through a cell-based assay including N-ethyl-N-nitrosourea (ENU) mutagenesis. We found that clinically reported L718 and G796 compound mutations appeared, consistent with their proximity to the binding site of brigatinib, and brigatinib-resistant quadruple mutants such as EGFR-activating mutation/T790M/C797S/L718M were resistant to all the clinically available EGFR-TKIs. BI-4020, a fourth-generation EGFR inhibitor with a macrocyclic structure, overcomes the quadruple and major EGFR-activating mutants but not the minor mutants, such as L747P or S768I. Molecular dynamics simulation revealed the binding mode and affinity between BI-4020 and EGFR mutants. This study identified potential therapeutic strategies using the new-generation macrocyclic EGFR inhibitor to overcome the emerging ultimate resistance mutants.Keywords
Funding Information
- MEXT | Japan Society for the Promotion of Science (22K18383, JP22K16205, JP22K18383, JP21K06510)
- Japan Agency for Medical Research and Development (JP22ck0106568h0003, JP23ama221201h0002 and JP23ama221210h0002, JP22ck0106568h0003)
- Princess Takamatsu Cancer Research Fund (N/A)
- Cell Science Research Foundation (N/A)
- FOCUS Establishing Supercomputing Center of Excellence
- Nippon Foundation (N/A)
- Takeda Science Foundation (N/A)
This publication has 45 references indexed in Scilit:
- Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patientsCancer Medicine, 2021
- Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination TherapyJournal of Thoracic Oncology, 2020
- Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid LeukemiaCancer Cell, 2019
- Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination TherapyJournal of Thoracic Oncology, 2019
- Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib TreatmentJournal of Thoracic Oncology, 2018
- EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistanceCancer Letters, 2017
- GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputersSoftwareX, 2015
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsThe Lancet Oncology, 2015
- Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistanceLung Cancer, 2013
- Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityCancer Cell, 2007